We chose protein characterization rather than RNA-Seq because these samples were not consented for genomics, and we chose K14 because of strong evidence linking K14 with laboratory analysis for tumor invasion in mouse and human [10] and clinical outcomes for breast cancer survival [12]. This evidence concerns the gene KRT14 and breast cancer.